May 6, 2023
In the RITURNS trial we demonstrated a substantial and clinically relevant reduction of relapse rates by primary use of Rituximab as compared to standard CNI therapy during a 12-month observation period, accompanied by a more favourable side effect profile [7]
In the RITURNS trial we demonstrated a substantial and clinically relevant reduction of relapse rates by...